Novo Nordisk partnered with Danish biotech Orbis Medicine to develop oral treatments for cardiometabolic diseases.
The collaboration utilizes the AI-powered nGen platform to replace traditional injectable therapies with oral macrocycles.
The agreement carries a total potential value of $1.4 billion for Orbis Medicine.
Financial terms include an upfront payment, development and commercial milestones, and tiered royalties on future sales.
Novo Nordisk will also make a direct strategic investment in the privately-held firm.